RT Journal Article
SR Electronic
T1 Evaluating disease severity in idiopathic pulmonary fibrosis
JF European Respiratory Review
JO EUROPEAN RESPIRATORY REVIEW
FD European Respiratory Society
SP 170051
DO 10.1183/16000617.0051-2017
VO 26
IS 145
A1 Hasti Robbie
A1 Cécile Daccord
A1 Felix Chua
A1 Anand Devaraj
YR 2017
UL http://err.ersjournals.com/content/26/145/170051.abstract
AB Accurate assessment of idiopathic pulmonary fibrosis (IPF) disease severity is integral to the care provided to patients with IPF. However, to date, there are no generally accepted or validated staging systems. There is an abundance of data on using information acquired from physiological, radiological and pathological parameters, in isolation or in combination, to assess disease severity in IPF. Recently, there has been interest in using serum biomarkers and computed tomography-derived quantitative lung fibrosis measures to stage disease severity in IPF. This review will focus on the suggested methods for staging IPF, at baseline and on serial assessment, their strengths and limitations, as well as future developments.Staging disease severity in IPF is challenging: a review of current available methods and future developments http://ow.ly/oBoJ30e8kVS